Atlas Trials

Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia

Clinical trial NCT01555268 · COMPLETED

Trial details

NCT number
NCT01555268
Sponsor
Roswell Park Cancer Institute
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Myelomonocytic Leukemia (M4)
Start date
2011-10-31
Primary completion
2013-09-24
Enrollment
24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.